Evidence map›Paper›PMID 25766898›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015

Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein.

Chul Hyoung Lyoo, Masamichi Ikawa, Jeih-San Liow, Sami S Zoghbi, Cheryl L Morse, Victor W Pike, Masahiro Fujita, Robert B Innis, William Charles Kreisl

Abstract readClinical Trial
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Systemic brain-body metabolic coupling patterns in amyotrophic lateral sclerosis: a whole-body [European journal of nuclear medicine and molecular imaging · 2026
    Article
  8. Article
  9. Article
  10. Comparing and combining TSPO-PET tracers in tauopathies.European journal of nuclear medicine and molecular imaging · 2026
    Article
  11. Cerebellar volumes' selective association with MoCA over MMSE: a diagnostic insight into mild cognitive impairment and mild dementia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. TSPO circadian pattern: a test-retest study of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  16. Review
  17. Unraveling the Effects ofInternational journal of molecular sciences · 2025
    Review
  18. Article
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chul Hyoung LyooDepartment of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Masamichi IkawaMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Jeih-San LiowMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Sami S ZoghbiMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Cheryl L MorseMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Victor W PikeMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Masahiro FujitaMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
Robert B InnisMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and.
William Charles KreislMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York kreislw@mail.nih.gov.

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Clinical Evaluation of PET RadiotracersZIAMH002852 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2009 to 2025
$48.6M
Intramural NIH HHS Z99 MH999999
6 · The paper itself

Abstract

unlabelledAlzheimer disease (AD) is associated with an increase in the brain of the 18-kDa translocator protein (TSPO), which is overexpressed in activated microglia and reactive astrocytes. Measuring the density of TSPO with PET typically requires absolute quantitation with arterial blood sampling, because a reference region devoid of TSPO does not exist in the brain. We sought to determine whether a simple ratio method could substitute for absolute quantitation of binding with (11)C-PBR28, a second-generation radioligand for TSPO.

methods(11)C-PBR28 PET imaging was performed in 21 healthy controls, 11 individuals with mild cognitive impairment, and 25 AD patients. Group differences in (11)C-PBR28 binding were compared using 2 methods. The first was the gold standard method of calculating total distribution volume (V(T)), using the 2-tissue-compartment model with the arterial input function, corrected for plasma-free fraction of radiotracer (f(P)). The second method used a ratio of brain uptake in target regions to that in cerebellum-that is, standardized uptake value ratio (SUVR).

resultsUsing absolute quantitation, we confirmed that TSPO binding (V(T)/f(P)) was greater in AD patients than in healthy controls in expected temporoparietal regions and was not significantly different among the 3 groups in the cerebellum. When the cerebellum was used as a pseudo-reference region, the SUVR method detected greater binding in AD patients than controls in the same regions as absolute quantification and in 1 additional region, suggesting SUVR may have greater sensitivity. Coefficients of variation of SUVR measurements were about two-thirds lower than those of absolute quantification, and the resulting statistical significance was much higher for SUVR when comparing AD and healthy controls (e.g., P < 0.0005 for SUVR vs. P = 0.023 for VT/fP in combined middle and inferior temporal cortex).

conclusionTo measure TSPO density in AD patients and control subjects, a simple ratio method SUVR can substitute for, and may even be more sensitive than, absolute quantitation. The SUVR method is expected to improve subject tolerability by allowing shorter scanning time and not requiring arterial catheterization. In addition, this ratio method allows smaller sample sizes for comparable statistical significance because of the relatively low variability of the ratio values.

Indexed as

Positron-Emission TomographyAgedAlzheimer DiseaseCerebellumFemaleHumansInflammationLigandsMaleMiddle AgedProtein BindingPyrimidinesReceptors, GABAReference StandardsLigands(methyl-(11)C)N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinaminePyrimidinesReceptors, GABATSPO protein, human11C-PBR28Alzheimer diseaseneuroinflammationpositron emission tomographyratio method

Identifiers

PMID25766898
PMCPMC4839390

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.